Actively Recruiting
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Led by Region Stockholm · Updated on 2024-01-19
100
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
Sponsors
R
Region Stockholm
Lead Sponsor
S
Sahlgrenska University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
CONDITIONS
Official Title
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with decompensated liver cirrhosis
- 18 years or older
- Healthy individuals 18 years or older can serve as controls
You will not qualify if you...
- Extrahepatic malignancy or recurrence within the last year
- Diagnosis of non-cirrhotic coagulopathy, coagulation disorder, or thrombophilia before inclusion
- Diagnosis of hematological diseases such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, or hemoglobinopathies
- Previous liver transplantation
- Blood transfusions in the last 7 days
- Treatment with platelet inhibitors or anticoagulants except prophylactic low molecular weight heparin; if prophylactic LMWH is used, sampling must occur more than 12 hours after the last injection with antiFXa test
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Karolinska University Hospital
Stockholm, Huddinge, Sweden, 14186
Actively Recruiting
Research Team
S
Sanna Norén, MD, PhDstudent
CONTACT
M
Maria Magnusson, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here